This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary MCTs Therapeutic Antibody Development
Background of MCTs
BioVenic runs a dedicated platform for veterinary MCTs therapeutic antibody development and delivers high-quality services covering the full antibody development workflow, ranging from gene synthesis and antibody preparation to purification and characterization, to support the exploration of MCTs-targeted cancer treatment strategies for companion animals. Cancer cells overexpressing MCTs can effectively sustain the pH conditions required for tumor proliferation, which renders these transport proteins promising targets for therapeutic intervention. Our platform is backed by experienced specialists and innovative technical approaches to guarantee reliable project outcomes.
Background of MCTs
| Full Name | Monocarboxylate transporters |
|---|---|
| Aliases | SLC16 |
| Target Profile | MCTs are members of the solute carrier 16 (SLC16) transporter family, playing a crucial role in the transport of short-chain monocarboxylates, hormones, nutrients, and amino acids. Due to their broad substrate specificity, these transport proteins are key in maintaining the steady state and functionality of endogenous molecules in circulation. The MCT family includes several members, with MCT1 and MCT4 exhibiting different expression patterns in various tissues and they are closely associated with a range of physiological and pathological processes. |
MoA of MCTs
The primary physiological function of MCTs 1-4 is the transport of monocarboxylates, including lactate, which helps maintain intracellular pH levels. In oncology, MCTs are particularly significant as they regulate lactate concentration within tumor cells. Tumor cells, even in the presence of sufficient oxygen, tend to undergo anaerobic glycolysis, producing large amounts of lactate. The elevated expression of MCTs in tumor cells assists in expelling excess lactate, thereby promoting tumor growth and survival.
Fig.1 Diagram of lactate transfer mediated by MCTs between cells.1, 2
Application in Veterinary Therapeutics
MCTs are highly expressed in various animal cancers, particularly in those tumors that are heavily reliant on glycolysis. MCT1 is rarely observed in the majority of melanocytes in normal canine oral mucosa, however, most canine oral melanomas express MCT1. The expression of MCT1 might play a significant physiological role in the survival of tumor cells within the microenvironment of oral melanoma tissue. Antibodies targeting MCTs can inhibit the function of MCTs, reducing the excretion of lactate by tumor cells, thereby disrupting the acidic microenvironment of the tumor and inhibiting tumor cell growth and spread. This could be effective in treating certain metabolically active companion animal tumors.
Veterinary MCTs Therapeutic Antibody Development Services
MCTs play a substantial role in some metabolically active solid tumors, hence antibody therapies targeting MCTs provide a novel treatment option for certain types of cancer in companion animals. BioVenic has established a diverse technology platform offering veterinary MCTs therapeutic antibody development services. We assist in developing veterinary therapeutic antibodies that can specifically bind to and regulate the activity of MCTs, providing safer and more effective treatment options for animals. Additionally, our services include antibody characterization and engineering to ensure the development of veterinary therapeutic antibodies with high affinity and safety.
Please click the link below for more information about our veterinary MCTs therapeutic antibody development services.
Why Choose Us?
We provide a one-stop solution for veterinary therapeutic antibody development, covering the entire process from antibody screening and preparation to engineering.
Our diverse technology platform offers a variety of choices, including traditional and cutting-edge techniques like hybridoma, single B cell, and phage display technologies.
Our team adheres to strict quality control to ensure the high purity and stability of antibody samples, aiding in better exploring the therapeutic potential of the antibodies.
Frequently Asked Questions
What core physiological function do MCT family proteins perform in animal cells under normal and tumor conditions?
MCTs (SLC16 monocarboxylate transporters) transport lactate, short-chain fatty acids and amino acids across cell membranes to maintain intracellular pH balance. In tumor cells, highly expressed MCT1/MCT4 expels massive lactate generated by aerobic glycolysis, neutralizing intracellular acidification to sustain tumor proliferation and survival.
What typical companion animal tumor relies heavily on MCT-mediated lactate transport for malignant progression?
Canine oral melanoma is the representative research model. Normal canine oral melanocytes barely express MCT1, while nearly all oral melanoma lesions show high MCT1 expression. This transporter supports tumor cells to survive in acidic microenvironments and promotes lesion progression and metastasis.
What anti-tumor mechanism do MCT-targeted therapeutic antibodies adopt for glycolysis-dependent pet tumors?
Neutralizing antibodies specifically bind cell-surface MCT transporters and block lactate efflux from tumor cells. Lactate accumulates inside cancer cells to disrupt intracellular pH homeostasis, suppress glycolytic energy supply, and ultimately inhibit tumor cell proliferation, invasion and distant spread.
What multi-antibody discovery platforms are available for developing anti-MCT veterinary therapeutic antibodies?
We provide four mature screening pipelines: mouse hybridoma technology, single B cell sorting from canine/feline peripheral blood, phage display biopanning, and transgenic mouse hybridoma systems to isolate high-specificity antibodies against canine MCT1/MCT4 antigens.
What species-adaptive antibody engineering services optimize anti-MCT antibodies for in vivo pet research?
We carry out CDR grafting, chimeric transformation and full caninization/felinization modification on primary murine antibodies. This drastically reduces heterologous protein components to lower immune rejection risk in dogs and cats, while retaining strong binding activity to block MCT lactate transport function.
Partner with BioVenic
MCTs are overexpressed in some types of companion animal cancers such as canine oral melanoma. BioVenic offers veterinary MCTs therapeutic antibody development services, encompassing not only antibody preparation but also precise engineering to ensure the high affinity and specificity of antibody samples. If you are considering developing veterinary MCTs therapeutic antibodies for animal cancer treatment, please contact us for more information!
References
- Liu, Tian, et al. "Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment." Cancer Management and Research (2023): 957-975.
- Image retrieved from Figure 3 "Schematic of lactate shuttling from cell to cell through the MCTs." Liu, Tian, et al., 2023, used under [CC BY 3.0], the image title was changed to "Diagram of lactate transfer mediated by MCTs between cells."